• Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=15153938).
  

PubMed=11242531; DOI=10.1089/10430340150504019
Bruning A., Kohler T., Quist S.R., Wang-Gohrke S., Mobus V.J., Kreienberg R., Runnebaum I.B.
Adenoviral transduction efficiency of ovarian cancer cells can be limited by loss of integrin beta3 subunit expression and increased by reconstitution of integrin alphaVbeta3.
Hum. Gene Ther. 12:391-399(2001)

PubMed=11733966; DOI=10.1006/gyno.2001.6425
Mobus V.J., Gerharz C.-D., Weikel W., Merk O., Dreher L., Kreienberg R., Moll R.
Characterization of a human carcinosarcoma cell line of the ovary established after in vivo change of histologic differentiation.
Gynecol. Oncol. 83:523-532(2001)

PubMed=15153938; DOI=10.1038/sj.cgt.7700727
Quist S.R., Wang-Gohrke S., Kohler T., Kreienberg R., Runnebaum I.B.
Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.
Cancer Gene Ther. 11:547-554(2004)